ROLE OF Ca-125 LEVEL AS A MARKER OF SEVERITY
OF PRE-ECLAMPSIA

Dr. Kazheen Sulaiman Abdulmanaf/ M.B.Ch.B/ Duhok hospital of Obstetrics and Gynecology
Dr. Ghada Sadullah Sulaiman/ M.B.Ch.B C.A.B.O.G/Department of obstetrics and gynecology/
Hawler Medical University College of Medicine

ABSTRACT
Background: Pre-eclampsia is an idiopathic hypertensive disorder of pregnancy, it seems that failure of trophoblast invasion and induction of placental inflammation led to the production of CA-125, hence can be used for identification of pre-eclampsia.
Objectives: This study aims at measuring maternal serum CA-125 with the possibility of being used in early diagnosis of sever preeclampsia so it may be used as a marker of the severity of the disease.
Methods: This case control study was conducted at Duhok Obstetrics and Gynecology teaching hospital during the period between January 2023 and September 2023. The study involved a 100 pregnant women, 50 normotensive patients (control group), and 50 pregnant women with pregnancy induced hypertension who were further subdivided to 3 subgroups, (n = 20) were PIH , (n = 20) were none severe pre-eclampsia, (n = 10) were severe pre-eclampsia subgroup. All were tested for serum CA125 along with the clinical and biochemical parameters for evaluating pregnant women whose pregnancies were complicated by hypertension.
Results: The mean level of CA-125 among the studied groups was statistically significant (p=0.000), the mean CA-125 in normotensive women was (19.02±6.259) and in and in gestational hypertension (24.24±10.863), non-severe (33.96±12.460) and in severe (62.89±16.011). The mean of CA-125 was increasing with increasing of the severity of Pre-eclampsia. Statistically significant positive correlation was found between CA-125 levels with MAP values (P= 0.000), a statistically significant negative correlation was found between CA-125 levels with platelet count and gestational age at time of termination and birth weight. CA-125 level at termination had the highest sensitivity and specificity for prediction of sever Pre-eclampsia with a cutoff of 41.72 U/ml.
Conclusions: The concentration of serum CA -125, is increased in preeclampsia and this was directly correlated with the severity of preeclampsia.
Keywords: Pre-eclampsia, CA-125, hypertensive disorder of pregnancy.

INTRODUCTION

Hypertension complicates 6–12% of all pregnancies (1), and involves two relatively benign conditions (chronic and gestational hypertension) and the more severe conditions of preeclampsia or eclampsia. Maternal mortality remains significant, particularly in less-developed countries, accounting for 18% of all maternal deaths worldwide (2). Pre-eclampsia complicates 3–5% of all pregnancies, and is characterized by placental and maternal vascular dysfunction that may lead to adverse outcomes such as severe hypertension, stroke, seizure (eclampsia), renal and hepatic injury, hemorrhage, fetal growth restriction, or even death (3). CA-125, or MUC 16, is a large transmembrane glycoprotein part of the mucin family, The subclass of membrane-associated mucins (MAMs).

They are glycosylated in specific manners and exhibit functions dependent on the tissue in which they are located (4). elevated levels in maternal serum originate from decidual cells affected by chorionic invasion or placental separation. The extension of decidual destruction and separation of trophoblasts from deciduas are proposed as the underlying mechanism for elevation in serum (CA-125) in preeclampsia (5, 6). There are few clinical studies related to the use of CA-125 in hypertensive disorders of pregnancy with conflicting results (7).

However, some studies reported positive correlations between serum CA-125 concentration and preeclampsia (8–11). Pre-eclampsia is traditionally defined as systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure. ≥ 90 mmHg, associated with de novo proteinuria above a threshold of 300 mg/24 h or above a urinary protein/urine creatinine ratio ≥ 0.3 mg/mg. This subtype of HDP has been associated with an increased risk for adverse maternal and fetal outcomes compared with other subtypes (12). Gestational hypertension is defined as new hypertension (Blood pressure ≥140/90) without significant proteinuria (13).

The American College of Gynecologists and Obstetricians (ACOG) and the International Society for the Study of Hypertension in Pregnancy (ISSHP) define the mild preeclampsia as gestational hypertension of at least 140/90 mmHg on two separate occasions ≥4 hours apart accompanied by significant proteinuria of >30 mgs/mmol, arising de novo after the 20th week of gestation in a previously normotensive woman and resolving completely by the 6th postpartum week (14).While the severe PE was defined as the presence of new onset of hypertension ≥160/110 mmHg occurs after 20 weeks' of gestation or superimposed on pre-existing hypertension and one or more of the following:
1. Proteinuria – spot urine protein: creatinine ratio ≥30 mg/mmol or ≥2+ on dipstick testing confirmed by a protein creatinine ratio test.
2. Other maternal organs dysfunction:
–renal insufficiency (creatinine >90 μmol/L, urine output of <80mL/4hr).
–liver involvement – elevated transaminases (ALT & AST) – at least twice upper limit of normal (right upper quadrant or epigastric abdominal pain).
– neurological complications (e.g., eclampsia, altered mental status, blindness, stroke or, more commonly, hyperreflexia when accompanied by clonus, severe headaches and persistent visual scotomata).
– haematological complications (thrombocytopenia – platelet count below 100 x 109/L,haemolysis).
3.Uteroplacental dysfunction (fetal growth restriction) (15,16).

CA-125 is a biomarker usually expressed at the atypical surface of the coelomic

epithelium. It is high molecular weight mucin-like glycoprotein. This antigen appears in 80% of ovarian epithelial carcinomas and non-malignant pelvic conditions such as endometriosis, fibroids, pregnancy and pelvic inflammation, liver disease, kidney failure, and lung, colon, breast, and adenomyosis cancers (17,18). However, there are many sources for CA125 during pregnancy such as fetal chorion, maternal decidua and amniotic are potential sources of high serum CA-125 levels in the first trimester of pregnancy due to damage in decidual cells during chorionic villus invasion in this stage, during the separation of placenta at birth in the postpartum period, the dynamics of serum CA-125 levels in the perinatal period still need to be explained (18).

Decidual cells affected by chorionic invasion or placental separation are a source of CA-125. The underlying mechanism proposed for the increased CA-125 levels in preeclampsia is the extension of decidual destruction and separation of trophoblasts from the decidua (19). Theories suggest a possible role in preeclampsia through the immunohistochemically proven presence of this marker in fetal tissues (pleura, peritoneum, and pericardium) and decidual tissue (20, 21).

Identifying a marker with a good predictive value for the severity of preeclampsia would allow for better selection of patients with severe pre- eclampsia and provide better management and timely interventions for the sake of the mother as well as the fetus. Moreover, it is a simple, affordable investigation, and it would allow better management of pre-eclampsia in limited resource settings. This study was conducted to see whether this marker has role as a severity marker and whether it can be used to improve pre-eclampsia management allowing a better selection of high-risk patients, aiding in decision making related to hospitalization and/or timing of birth.

Patients and Methods:
This study was a case control study conducted at Duhok Obstetrics & Gynecology teaching Hospital in Duhok city, Kurdistan region, Iraq during the period between January 2023 and september 2023. After Ethical approval obtained from Scientific Council of Obstetrics& Gynecology / Iraqi Board for Medical Specializations and from the scientific committee of the Directorate of general of health ⁄ Duhok. Verbal consent was obtained from the patient before enrollment.

The study involved a 100 pregnant women, 50 were normotensive patients (control group), and 50 pregnant women with PIH (case group) , which was further subdivided to GH (20), and none sever PE (20) and sever PE (10) all tested for serum CA125.

Definition of cases: Mild PE: Was defined as gestational hypertension of at least 140/90

mmHg on two separate occasions ≥4 hours apart accompanied by significant proteinuria of normotensive woman and resolving completely by the 6th postpartum week (14).

Severe PE: was defined as the presence of new onset of hypertension ≥ 160/110 mmHg occurs after 20 weeks' gestation (in a woman who had normal blood pressure before 20 weeks' gestation) or superimposed on pre-existing hypertension and one or more of the following: proteinuria – spot urine protein:creatinine ratio ≥30 mg/mmol or ≥2+ on dipstick testing confirmed by a protein creatinine ratio test. Other maternal organ dysfunction: renal insufficiency (creatinine >90 μmol/L, urine output of <80mL/4hr. liver involvement – elevated transaminases (ALT & AST) – at least twice upper limit of normal (right upper quadrant or epigastric abdominal pain).

Control group included: Any pregnant normotensive woman who was admitted to labor ward and accepted to participate in the research. Inclusions Criteria included : Pregnant women aged between 18-45 yrs. , Pregnant women admitted to labor ward and ended with vaginal or Cesarean delivery , Pregnant women with confirmed proteinuria and high blood pressure and other biochemical and clinical markers consistent with HDP .Exclusions Criteria included: a history of chronic hypertension, renal or hepatic disease, diabetes mellitus, known gynecologic pathology (ovarian or uterine disease), multiple pregnancies, known fetal anomalies. pregnancies achieved by ART and Patients refusal of enrollment.

No patient preparation is needed prior to the collection of the sample, nearly 3cc of blood was drawn from the patients through Venipuncture and collected into a Yellow Cap Vacuum Gel and Clot Activator Blood Collection Tube analyzing serum shortly after centrifugation of the obtained blood specimen. The serum specimen can then be stored at either 4°C (1-5 days) or -20°C (2 weeks to 3 months) in the short term or -70°C in the long term to ensure stability (22). The blood was taken directly for the test but if it was not possible the sample was stored for 1-5 days and then transported to the laboratory, the samples were measured using the ECLIA method.

The reference range of CA 125 is 0-35 units/mL (0-35 kU/L). The cutoff of 35 kU/L for CA 125 was determined from the distribution of values in healthy individuals to include 99% of the normal population (23).

Statistical analysis: The study data were summarized in sheets of Microsoft Excel 2010. The statistical analysis performed by using IBM-SPSS 26. The means and standard deviations for the studied parameters were calculated. One-Way ANOVA was done to calculate the difference among more than three groups and the post Hoc

test was done afterward for the significant ANOVA test. The t-test for independent two means was used. ROC test was done to determine the area under the curve, sensitivity,

specificity, positive and negative predictive values for CA-125. *P*-value ≤ 0.05 considered as significant.

RESULTS:

This study included 100 women admitted to DMH. The comparison of the studied parameters among the studied group (PMH, PDH, ANC, NICU admission, mode of delivery) was demonstrated in table (1) and showed that only 15.0% and 40.0% of the women with gestational hypertension and severe PE respectively reported previous history of PE while 60.0% of the mild PE reported such history; the difference was statistically significant (p=0.014). Regarding NICU admission 50% in severe PE group were admitted as opposed to 10% and 15% in GH and mild group respectively, the difference was statistically significant (p=0.03).

Table 3.1: The Comparison of the Study Parameters among the Study Groups.

		GH (n = 20) No. (%)	Mild PE (n=20) No. (%)	Severe PE (n=10) No. (%)	p-value*
History of PE	Yes	3(15.0/)	12(60.0)	4(40.0)	**0.014**
	No	17(85.0)	8(40.0)	6(60.0)	
Dexamethasone	Yes	7(35.0)	3(15.0)	3(30.0)	0.413
	No	13(65.0)	17(85.0)	7(70.0)	
Aspirin	Yes	4(20.0)	7(35.0)	2(20.0)	0.639
	No	16(80.0)	13(65.0)	8(80.0)	
ANC	Yes	14(70.0)	13(65.0)	7(70.0)	1.000
	No	6(30.0)	7(35.0)	3(30.0)	
Admission to NICU	Yes	2(10.0)	3(15.0)	5(50.0)	0.033
	No	18(90.0)	17(85.0)	5(50.0)	
Mode of delivery	Vaginal	8(40.0)	10(50.0)	4(40.0)	0.845
	AVD	2(10.0)	2(10.0)	0(0.0)	
	CS	9(50.0)	8(40.0)	6(60.0)	

Anti HT	Yes	19(95.0)	19(95.0)	10(100.0)	1.000
	No	1(5.0)	1(5.0)	0(0.0)	
LMWH	Yes	0(0.0)	2(10.0)	0(0.0)	0.347
	No	20(100.0)	18(90.0)	10(100.0)	

The comparison of the study characteristics including age, parity, gestational at birth, and birth weight among the studied groups was demonstrated in Table 3.2 which showed the means of maternal age and parity were lower in the normotensive group (27.64±5.885) and (1.66±1.349) respectively, while the mean gestational age was higher in the normotensive group (38.14±1.690) in comparison to the cases groups but with no statistically significant differences. The study also showed a statistically significant difference concerning the birth weight (p=0.000) and showed that the mean birth weight for neonates of the normotensive women (3282.8±539.784 g) by using post hoc test was significantly higher than those among the gestational hypertension (2942.5±370.374 g), mild PE (2936.0±347.129 g), and severe PE (2565.0±248.383 g) with no significant differences among the cases groups themselves.

Table 3.2: Comparison of the Study Characteristics among the Studied Groups.

	Normotensive (n = 50)	GH (n = 20)	mild PE (n = 20)	Severe PE (n = 10)	p-value*
	Mean ±SD	Mean ±SD	Mean ±SD	Mean ±SD	
Age	27.64±5.885	30.30±7.854	29.10±6.632	28.10±7.578	0.476
Parity	1.66±1.349	2.00±1.589	1.80±1.765	1.70±2.162	0.875
GA at birth (weeks)	38.14±1.690	37.60±1.957	37.95±1.877	36.80±1.751	0.165
Birth weight (grams)	3282.8±539.784 A	2942.5±370.374 B	2936.0±347.129 B	2565.0±248.383 B	**0.000**

*One-Way ANOVA with post hoc test; same letters mean no significance while different letter

mean significant difference

Comparison of the measurements and investigations among the studied groups was demonstrated in Table 3.2. This table elicited that the mean MAP (95.82±13.137) was statistically lower tin the normotensive group in comparing to the remaining cases groups (p=0.000). The mean

platelet counts among the women with severe PE (154.80±93.542)
 was statistically lower than those of the cases groups and normotensive group (p=0.000).
Regarding S. uric acid, SGOT, and SGPT, the women in the normotensive group had the lowest level with the highest levels in the severe PE; the differences were statistically significant.
The mean level of CA-125 among the studied groups was statistically significant (p=0.000), the post hoc test showed that the real differences were between normotensive women (19.02±6.259) and women with PE whether non-severe (33.96±12.460) or severe (62.89±16.011) but not with women with gestational hypertension (24.24±10.863).
Albumin in urine among the severe PE was significantly higher than that in mild PE while no significant difference was found between these two groups concerning protein-creatinine ratio. BMI, Hb, blood urea, S. creatinine showed no significant statistical differences.

Table 3.2: Comparison of the Study Characteristics among the Studied Groups.

	Normotensive (n = 50)	GH (n = 20)	mild PE (n = 20)	Severe PE (n = 10)	p-value*
	Mean ±SD	Mean ±SD	Mean ±SD	Mean ±SD	
Age	27.64±5.885	30.30±7.854	29.10±6.632	28.10±7.578	0.476
Parity	1.66±1.349	2.00±1.589	1.80±1.765	1.70±2.162	0.875
GA at birth (weeks)	38.14±1.690	37.60±1.957	37.95±1.877	36.80±1.751	0.165
Birth weight (grams)	3282.8±539.784 A	2942.5±370.374 B	2936.0±347.129 B	2565.0±248.383 B	**0.000**

*One-Way ANOVA with post hoc test; same letters mean no significance while different letter mean significant difference

Comparison of the measurements and investigations among the studied groups was demonstrated in Table 3.2. This table elicited that the mean MAP (95.82±13.137) was statistically lower tin the normotensive group in comparing to the remaining cases groups (p=0.000). The mean platelet count among the women with severe PE (154.80±93.542) was statistically lower than those of the cases groups and normotensive group (p=0.000).

Regarding S. uric acid, SGOT, and SGPT, the women in the normotensive group had the lowest level with the highest levels in the severe PE; the differences were statistically significant.

The mean level of CA-125 among the studied groups was statistically significant (p=0.000), the post hoc test showed that the real differences were between normotensive women (19.02±6.259) and women with PE whether non-severe (33.96±12.460) or severe (62.89±16.011) but not with women with gestational hypertension (24.24±10.863).

Albumin in urine among the severe PE was significantly higher than that in mild PE while no significant difference was found between these two groups concerning protein-creatinine ratio. BMI, Hb, blood urea, S. creatinine showed no significant statistical differences.

Table 3.3: Comparison of the Measurements and Investigations among the Studied Groups.

	Normotensive (n = 50)	GH (n = 20)	mild PE (n = 20)	Severe PE (n = 10)	p-value
	Mean ±SD	Mean ±SD	Mean ±SD	Mean ±SD	
MAP	95.82 ±13.137 A	113.58 ±5.678 B	117.47 ±7.286 C	131.95 ±8.749 D	**0.000***
BMI	25.80±4.150	24.25±4.216	25.75±4.399	25.30±4.522	0.566*
HB	10.71±1.396	11.08±1.346	11.04±1.422	11.14±1.309	0.635*
Platelet count	292.5 ±87.216 A	321.1 ±108.436 A	272.0 ±76.211 A	154.80±93.542 B	**0.000***
S uric acid	3.91 ±0.964 A	4.67 ±1.050 B	5.29 ±1.173 BC	6.19 ±1.153 CD	**0.000***

Blood urea	18.28±6.104	18.51±4.060	19.69±4.137	22.97±7.722	0.105*
S creatinine	0.523±0.306	0.536±0.235	0.618±0.236	0.545±0.264	0.630*
Albumin in urine	------	------	1.95±0.223	2.60±0.516	**0.000****
SGPT	16.62 ±6.104 A	26.50 ±11.00 A	22.75 ±7.832 A	91.50 ±99.052 B	**0.000***
SGOT	14.02 ±5.804 A	26.45 ±10.128 A	21.26 ±8.271 A	71.0 ±64.296 B	**0.000***
Protein creatinine ratio	------	------	0.820±0.447	0.820±0.358	1.000**
S Ca125	19.02 ±6.259 A	24.24 ±10.863 A	33.96 ±12.460 B	62.89 ±16.011 C	**0.000***

*One-Way ANOVA with post hoc test; same letters mean no significance while different letters mean significant difference   **t-test for independent two means.

Statistical significance of CA-125 levels between study subgroups was evaluated by using Tukey post hoc test which showed that the association between each two group was statistically significant (P=0.000) except between normotensive group and gestational hypertension group (P=0.198) as demonstrated in Table 3.4.

Table 3.4: Statistical Significance of CA-125 UI/mL Levels Between the Study Subgroups

Studied groups	Significance	GH	mild PE	Severe PE	Normotensive
GH	p-value	—	0.013	0.000	0.198
Non-Severe PE	p-value		—	0.000	0.000
Severe PE	p-value			—	0.000
Normotensive	p-value				—

The correlations of the CA-125 mean levels with clinical–biological parameters was demonstrated in Table 3.5 by using Pearsons's Correlation Coefficient (r) which revealed significant direct correlations with MAP(0.606), S.uric acid (0.394), SGOT(0.503) , SGPT(0.458) and albumin in urine (0.608) and indirect correlations with platelet count (-0.327), gestational age (-0.258), and birth weight(-0.329), while no significant correlations were found with S. creatinine and protein-creatinine ratio.

Table 3.5: CA-125 Levels' Correlations with Clinical–biological Parameters.

Parameter	Pearsons's Correlation Coefficient (r)	p-Value
MAP	0.606	**0.000**
Platelets count	-0.327	**0.001**
S Uric Acid	0.394	**0.000**
SGPT (mg/dL)	0.458	**0.000**
SGOT(mg/dL)	0.503	**0.000**
Creatinine (mg/dL)	0.031	0.758
Protein–Creatinine Ratio	0.163	0.388
Gestational age at birth	-0.258	**0.010**

|		
Birth weight	-0.329	**0.001**
Albumin in Urine	0.608	**0.000**

The ROC test to estimate the critical area under the curve for the CA-125 was demonstrated in Table 3.5 and Figure 3.1. This table revealed significant association for this indicator with the severity of the PE with area under the curve was (0.940), while the area of the S.uric acid was lower (0.856) and not significant. The cut-off points with sensitivity, specificity, PPV, and NPV were demonstrated in Table 3.6 and showed that the optimal cut-off point was 41.72 mUI/mL.

**Table 3.6: ROC test and area Under the Curve for the validity of serum Ca 125 test.**

Area	Std. Error[a]	p-value[b]	Asymptotic 95% Confidence Interval	
			Lower Bound	Upper Bound
0.940	0.043	**0.000**	0.856	1.000

Under the nonparametric assumption   b. Null hypothesis:true area=0.5

Figure 2 : ROC Test and Area under the Curve for the Validity of Serum Ca 125 test.

Figure 3: ROC Test and Area Under the Curve for the Validity of Serum Ca125 & S.uric acid tests.

Discussion

Hypertensive disorder during pregnancy have a substantial threat to both maternal and fetal health conditions (24). Preeclampsia is one of the most well-known medical conditions that belong to this disease spectrum, which also accounts for one of the most common documented gestational complications, with a prevalence of approximately 2 to 15% of all pregnancies (25,26). The exact cause of PE is unknown however; the basic pathology is endothelial dysfunction and intense vasospasm (27).The current study found no statistically significant differences among the normotensive group and the three gestational hypertensive , mild and sever preeclampsia regarding maternal age , parity and gestational age at birth, However the means of maternal age and parity were lower in the normotensive group, while the mean gestational age was higher in the normotensive group , these results coincide with the results of Thuria Ahmed et al (28) prospective case control study at Suez canal university hospitals in Egypt regarding maternal age between normotensive and mild PE and sever PE but it contradicts it in showing statically difference among the above mentioned groups regarding gestational age at birth these finding was confirmed by Danisman and Rousso, 2011 (29) which also revealed statistically difference among the groups regarding gestational age which can be attributed to preterm delivery of the fetuses in preeclampsia with increasing severity of the disease.

 This study also showed a statistically significant difference concerning the birth weight and showed that the mean birth weight for neonates of the normotensive women was significantly higher than those among the gestational hypertension, mild PE, and severe PE, with no

significant differences among the cases groups themselves.

In this study the mean serum concentration of CA-125 in mild and severe PE which indicates that serum CA125 level increase with increasing severity of preclampsia this was in agreement with Thuria Ahmed et al (2019) in which the mean serum concentration of CA-125 was (32.59±1.6) , (39.70±1.19)., (52.92±2.88) in control mild and severe PE, also the same conclusion was reached by Karamanand Ark (2013) (30) and the results of Geya Gottipati et al., (2019) (31) a cross-sectional study was conducted at a Tertiary Care Hospital, Mangaluru, India. In which the mean serum concentration of CA-125 was (14.7±8.4) , (56.6±88.2)., in GH and severe preeclampsia group respectively.

This increase may be related to impaired placentation which causes intermittent disruption of placental perfusion, oxidative stress and systemic inflammatory response which worsens with the severity of preeclampsia. This is in turn favors the hypothesis that increasing severity of the disease leads to increased release of CA-125. There was a slight deference in the Mean value of CA-125 in the preeclampsia group in the present study was 62.89 IU/mL which was near the results of Bhattacharya and Saha (58.5 IU/mL) (32), whereas value was slightly higher when compared to Karaman et al. (38.8 IU/mL) (33) and Hassan et al. (38.04 IU/mL) (34).

This difference can be the result of wide difference in the standard deviation obtained in this study as much higher values of CA-125 were observed in a few patients with severe form of PE resulting in higher mean values compared to other two above- mentioned studies. Furthermore, in the present study, the results showed that the mean CA-125 had a significant difference in women of the control group compared with mild preeclampsia, which was similar to the results of other studies (35,36,37). Only in the study conducted by Karaman et al., no significant difference was reported between the two groups of control and mild preeclampsia (33) and these recent studies compared to the present study, or the lack of control founders and also the method of conducting the study.

The study also concluded that; The mean level of Ca-125 among the studied groups was statistically significant and the real differences were between normotensive women and women with PE whether non-severe or severe but not with women with gestational hypertension. This A prospective case-control study which was carried out in the department of gynecology and obstetrics at Baghdad teaching hospital in 2015 which showed statistically significant differences between control and mild preeclamptic group and between mild and severe preeclamptic group. Which is also mentioned by Ozat et al., 2010 study done in Turkey, in which they found that the Ca125 is biochemical marker that reflects the severity of the underlying inflammation processes in PE in third trimester (38). Also same results obtained by Dr. Miami Abdul Hassan Ali et ., (39) A case control study was carried out in the department of gynecology and obstetrics at Al-Yarmouk teaching hospital (Baghdad\Iraq) in which it showed that CA-125level was significantly higher in preeclampsia and eclampsia than control group.

The results of the different mentioned studies earlier contradicts the results of Bon et.al 2001(40) who

assessed Ca125 and Ca15-3 and compared their levels in women with a normal pregnancy outcome and pathological pregnancies including PE, they found that maternal serum levels of Ca125 & Ca15-3 were significantly higher in the first and the third trimester of pregnancy, but no significant difference found in normal pregnancy from that obtained in pathological one including PE patients but this finding might probably be due to different timing of measurement during pregnancy in their study (first & third trimesters) while the other studies where taken after 24 weeks gestational age that's to say patients in late second and third trimester.

 In the current study A cut-off value was calculated using the receiver operating characteristics (ROC)Curve which was (0.685). The best cut off value for severe pre-eclampsia, with a sensitivity of 90.0% and specificity of 90.0%, was a CA-125 of 41.72 U/mL. This level was associated with a negative predictive value (NPV) of 90.0%.

The current study compared ca125 with s. uric acid which revealed significant association for the Ca 125 with the severity of the PE with area under the curve was (0.940) with confidence interval upper limit equal to 1.000 which indicates best accuracy and more have more value for prediction of the disease while the area of the S.uric acid was lower (0.685) and not significant with confidence interval upper limit equal to 0.884. The best value of serum uric acid for the diagnosis of severe preeclampsia was 5.2500 with a lower sensitivity of 80% and a specificity of 60% than that of serum ca125 concentration.is in concordant with that revealed by Wasan W. Ibrahem et al., (37).

Conclusions: The concentration of serum Cancer antigen -125, is increase in preeclampsia and there is a wide difference between gestational HTN, mild and severe form PE being more increased in sever form of the disease. There was a correlation between increase serum CA125 with adverse fetal perinatal outcome in severe cases of pre-eclmpsia but further studied are needed to confirm this correlation.

References
1. Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure inPregnancy. Am J Obstet Gynecol 2000;183:S1– S22.
2. Khan, K.S.;Wojdyla, D.; Say, L.; Gülmezoglu, A.M.; Van Look, P.F. WHO Analysis of Causes of Maternal Death: A Systematic Review. Lancet 2006, 367, 1066–1074.

3. ACOG Committee on Practice Bulletins: Obstetrics. ACOG Practice Bulletin No. 33. Diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol 2002;99:159–167

4. Bottoni, P.; Scatena, R. The Role of CA 125 as Tumor Marker: iochemical and Clinical Aspects. In Advances in Cancer Biomarkers; Scatena, R., Ed.; Advances in Experimental Medicine and Biology; Springer Netherlands: Dordrecht, The Netherlands, 2015; Volume 867, pp. 229–244. ISBN 978-94-017-7214-3.

5. Duran-Reyes G, Gomes-Melendez MR, Morali De, La Brena G, Mrecado- Pichardo E, Medina-Navarro R, Hicks-Gomez JJ. Nitric oxide synthesis inhibition suppresses implantation and decreases CGMP concentration and protein peroxidation. Life Sci. 2001;65:2259–2268.

6. Roberts JM. Endothelial SeminReprodEndocrinol. 1998;16:5–15. dysfunction in preeclampsia.

7. Bon GG, Kenemans P, Verstraeten AA, Go S, Philipi PA, Van Kamp GJ, et al. Maternal serum CA125 and CA15-3 antigen levels in normal and pathological pregnancy. Fetal Diagn Ther. 2001; 16(3):166– 72. https://doi.org/10.1159/000053903 PMID: 11316933

8. Osanyin GE, Okunade KS, Ayotunde Oluwole A. Association between serum CA125 levels in preeclampsia and its severity among women in Lagos, South-West Nigeria. Hypertens Pregnancy2018; 37(2):93–7. https://doi.org/10.1080/10641955.2018.1460667 PMID: 29718786

9. Sproston NR, Ashworth JJ. Role of C-Reactive Protein at Sites of inflammation and infection. Frontiers in Immunology 2018; 9(April):1–11. https://doi.org/10.3389/fimmu.2018.00754 PMID: 29706967.

10. Bellos I, Pergialiotis V, Loutradis D, Papapanagiotou A, Daskalakis G. Serum CA-125 levels in preeclampsia: A systematic review and meta-analysis. Int J Clin Pract. 2019; 73(10):1–7. https://doi.org/ 10.1111/ijcp.13380 PMID: 31162767.

11. Ali M, Hameed BH, Kamel W. The Association of Serum Cancer Antigen 125 and C—reactive protein Level with The Severity of Preeclampsia. Karbala J. Med. Vol. 5, No.1, Dec, 2012:1322–1327.

12. Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet. Gynecol. 2020, 135, e237.

13. National Institute for Health and Care Excellence. Hypertension in Pregnancy: Diagnosis and Management. Clinical Guideline CG107. London: NICE, 2010. Available at https://www.nice.org.uk/ guidance/cg107.

14. Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222. Obstet. Gynecol. 2020; 0000000000003891. 135: e237–e260. doi: 10.1097/AOG.

15. Rolnik DL, Wright D, Poon LCY, et al. ASPRE trial: Performance of screening for preterm pre-eclampsia. Ultrasound in Obstetrics & Gynecology. 2017; 50(4): 492-495. https://doi.org/10.1002/uog. 18816.

16. Tranquilli AL. Introduction to ISSHP new classification of preeclampsia. Pregnancy Hypertens.

2013 Apr;3(2):58-9. doi: 10.1016/j.preghy.2013.04.006.

17. Patil MB, Lavanya T, Kumari CM, Shetty SR, Gufran K, Viswanath V, et al. Serum ceruloplasmin as cancer marker in oral pre-cancers and cancers. J Carcinog. 2021;20:15.

18. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. ObstetGynecol. 2013;122(5):1122-31.

19. Sanford BH, Labbad G, Hersh AR, Heshmat A, Hasley S. Leveraging American College of Obstetricians and Gynecologists Guidelines for Point-of- Care Decision Support in Obstetrics. Appl Clin Inform. 2021;12(4):800-7.

20. Fuith, L.C.; Daxenbichler, G.; Dapunt, O. CA 125 in the Serum and Tissue of Patients with Gynecological Disease. Arch. Gynecol. Obstet. 1987, 241, 157–164

21.Zeimet, A.G.; Müller-Holzner, E.; Marth, C.; Daxenbichler, G.; Dapunt, O. Tumor Marker CA-125 in Tissues of the Female Reproductive Tract and in Serum during the Normal Menstrual Cycle. Fertil. Steril. 1993, 59, 1028–1035.

22. Fleisher M, Dnistrian A, Sturgeon C, Lamerz R,Witliff J. Practice guidelines and recommendations for use of tumor markers in the clinic. Tumor Markers. Physiology, pathobiology, technology and clinical applications. Washington: AACC Press; 2002. 33–63.

23.Shih M, Sokoll L, Chan DW. Ovarian cancer. Diamandis EP, Fritsche HA, Lilja H, Chan DW, Schwartz MK, eds. Tumor Markers: Physiology, Pathobiology, Technology and Clinical Applications. Washington, DC: AACC Press; 2002. 239-52.

24. Malatyalioglu E, Ozer S, et al. CA-125 levels in ruptured and unruptured tubal ectopic pregnancies. J Obstet Gynaecol Res 2006;32(4):422–427. DOI: 10.1111/j.1447-0756.2006.00424.x.

25.Say L., Chou D., Gemmill A., Tunçalp Ö., Moller A.-B., Daniels J., Gülmezoglu A.M., Temmerman M., Alkema L. Global causes of maternal death: A WHO systematic analysis. Lancet Glob. Health. 2014;**2**:E323–E333. doi: 10.1016/S2214-109X(14)70227-X.

26. Jeyabalan A. Epidemiology of preeclampsia: Impact of obesity. Nutr. Rev. 2013;**71**:S18–S25. doi: 10.1111/nure.12055.

27. Mou A.D., Barman Z., Hasan M., Miah R., Hafsa J.M., Das Trisha A., Ali N. Prevalence of preeclampsia and the associated risk factors among pregnant women in Bangladesh. Sci. Rep. 2021;**11**:21339. doi: 10.1038/s41598-021-00839-w.

28. Thuria Ahmed fahim , Eman Ahmed Kishk , Mamdouh El-Mhdy Said , et al. serum concentration of cancer antigen 125 in normal and PE pregnancies. Egypt . J. Fertil.steril.volume 23 , number2 , jan 2019.

29. Dnisma N and Rousso D(2011): ArchGYnecol Obstet 284:607-612DOI:10100*7s00404-0101736-2.

30. Karaman E and ArKHC (2013): Mater-nal serum ca125 level is elevated in severe preeclampsia.10.1061.j.preghy.

31. Geya Gottipati1, Kantharaju Supriya 2 et al. Maternal Serum Cancer Antigen 125: A Marke of Severity of Preeclampsia. Journal of South Asian Federation of Obstetrics and Gynaecology, Vol.11 Issue 3 (May–June 2019).

32. Bhattacharya DA, Saha R. Serum concentrations of CA-125 in normal and Preeclamptic pregnancies. IOSR J Pharm 2014;8:14–17. DOI: 10.9790/3013-0408014017.

33.Karaman E, Karaman Y, et al. Maternal serum CA-125 level is elevated in severe preeclampsia. Pregnancy Hypertens 2014;4(1):29–33. DOI: 10.1016/j.preghy.2013.08.003.

34.Hassan MA, Hameed BH, et al. The Association of Serum Cancer Antigen 125 and C - reactive protein Level.

35.Ibrahem WW, Al-Assaly RK, Al-Haddad NS. CA-125, plasma fibrinogen and C-reactive protein in correlation with severity of preeclampsia. J Fac Med Baghdad.2017;59(1):31-5.

36.De Cecco L, Marchionni L, Gariboldi M, Reid JF, Lagonigro MS, Caramuta S, et al. Gene expression profiling of advanced ovariancancer: characterization of a molecular signature involving fibroblast growth factor 2. Oncogene. 2004;23(49):8171-83.

37.Deruelle P, Girard JM, Coutty N, Subtil D. Prevention of preeclampsia. Ann. FrAnesthReanim. 2010; 29(3):e31-e35.

38. Ozat M, Pektas MK and Yenicesu O: Serum concentrations of CA-125 in normal and preeclamptic pregnancies. In: Archives Of Gynecology And   Obstetrics,2010:1-9.

39.Miami Abdul Hassan Ali, Dr. Ban Hadi Hameed , Dr. Warqaa Mahdi Kamel, et al : The Association of Serum Cancer Antigen 125 and C – reactive protein Level with The Severity of Preeclampsia. Karbala J. Med. Vol.5, No.1, Dec, 2012.

40.Bon GG, Kenemans P and Verstraeten AA. Maternal serum Ca125 and Ca15-3 antigen levels in normal and pathological pregnancy. In: Fetal Diagn Therpy. 2001;16(3):166-72.